Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23309276 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11DGAT1CA12CA1 | |
| SCHEMBL28964604 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11DGAT1CA12CA1 | |
| SCHEMBL22098411 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11DGAT1CA12CA1 | |
| SCHEMBL23971392 | 0.79 | DGAT1 (0.31) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL46332 | 0.75 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL19599855 | 0.74 | CES2 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL19599927 | 0.72 | CES2 (0.34) | — | |
| SCHEMBL23970489 | 0.71 | HDAC3 (0.31) | — | |
| SCHEMBL20325417 | 0.69 | EPHX2 (0.36) | — | |
| SCHEMBL46780 | 0.68 | DGAT1 (0.38) | CYP4F2CYP4A11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | CYP4F2 2632/4885CYP4A11 2870/4885DGAT1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.